Top-News

Transmedics Group Aktie News

Aktie
WKN:  A2PH5P ISIN:  US89377M1099 US-Symbol:  TMDX Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
138,63 $
-1,47 $
-1,05%
118,93 € 04.12.25
Depot/Watchlist
Marktkapitalisierung *
3,32 Mrd. €
Streubesitz
-
KGV
61,73
Index-Zuordnung
-

Transmedics Group News

18.11.25 - PR Newswire
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference PR Newswire
31.10.25 - PR Newswire
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
29.10.25 - PR Newswire
TransMedics Reports Third Quarter 2025 Financial Results
TransMedics Reports Third Quarter 2025 Financial Results PR Newswire
15.10.25 - PR Newswire
TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025
TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025 PR Newswire
22.09.25 - PR Newswire
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
TransMedics and Mercedes-​Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy PR Newswire
22.09.25 - PR Newswire
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
TransMedics and Mercedes-​Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy PR Newswire
25.08.25 - PR Newswire
TransMedics to Present at Upcoming September Investor Conferences
TransMedics to Present at Upcoming September Investor Conferences PR Newswire
04.08.25 - PR Newswire
TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial
TransMedics Receives FDA IDE Approval to Initiate Next-​Generation OCS Heart Trial PR Newswire
01.08.25 - PR Newswire
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
30.07.25 - PR Newswire
TransMedics Reports Second Quarter 2025 Financial Results
TransMedics Reports Second Quarter 2025 Financial Results PR Newswire
29.07.25 - PR Newswire
TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference
TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference PR Newswire
16.07.25 - PR Newswire
TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025
TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025 PR Newswire
27.05.25 - PR Newswire
Kuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law Firm PR Newswire
27.05.25 - PR Newswire
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
20.05.25 - PR Newswire
TransMedics to Present at Upcoming June Investor Conferences
TransMedics to Present at Upcoming June Investor Conferences PR Newswire
08.05.25 - PR Newswire
TransMedics Reports First Quarter 2025 Financial Results
TransMedics Reports First Quarter 2025 Financial Results PR Newswire
24.04.25 - PR Newswire
TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025
TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025 PR Newswire
14.04.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in TransMedics Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - TMDX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in TransMedics Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - TMDX ...
14.04.25 - PR Newswire
INVESTOR DEADLINE TOMORROW: TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TMDX
INVESTOR DEADLINE TOMORROW: TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TMDX PR Newswire
13.04.25 - PR Newswire
TMDX Investors Have Final Opportunity to Lead TransMedics Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
TMDX Investors Have Final Opportunity to Lead TransMedics Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »